Table 1 Subjects and associated metadata.

From: Oral microbiome and mycobiome dynamics in cancer therapy-induced oral mucositis

Cancer

Age

Sex

Stage

P16

Surgery

Radiation

Chemotherapy

Dentition

Galera

Control

Age

Sex

Oral Cavity

         

OM-3

61

F

OM-1

61

M

IVa, (T4, N0, M0)

+

Unresectable

70 Gy

Carbo/ Tax

Poor

No

OM-4

56

F

OM-2

55

M

IVA (T4a, N0, M0)

Yes Margin (−)

60 Gy

Cis 100 Q3wk

Excellent

No

OM-5

24

F

OM-14

75

F

II (T2 NX M0)

Yes Margin (+)

70 Gy

Carbo/ Tax

Poor

No

OM-6

51

F

OM-20

73

F

III (T3, N0, M0)

Yes Margin (+)

70 Gy

Cis 40 Weekly

Excellent

Yes

OM-12

85

M

OM-22

62

F

IVA (T2, N2b, M0)

Yes Margin (−)

60 Gy

Cis 100 Q3wk

Excellent

Yes

OM-15

73

M

OM-26

52

M

III (T2, N1 M0)

Yes Margin (−)

60 Gy

Carbo/ 5FU

Excellent

No

OM-18

58

F

OM-34

75

F

IVA (T4, N2b, M0)

Yes Margin (−)

60 Gy

Cis 40 Weekly

Poor

No

OM-23

65

M

OM-9

78

F

II(T2, N0, M0)

Yes Margin (−)

60 Gy

None

Excellent

No

OM-25

60

F

Oro-Pharynx

         

OM-27

60

F

OM-10

72

F

I (TX, N1, M0)

+

No

70 Gy

Carbo/ Tax

Excellent

No

OM-30

72

M

OM-11

80

F

I (T2, N1 M0)

+

No

70 Gy

Carbo/ Tax

Excellent

No

OM-32

48

M

OM-13

47

M

IVa (T2, N2c M0)

No

70 Gy

Cis 40 Weekly

Poor

No

   

OM-16

61

M

I (T1, N1, M0)

+

Yes

70 Gy

Cis 100 Q3wk

Excellent

Yes

   

OM-17

36

M

IVa (T3, N2b M0)

No

70 Gy

Cis 100 Q3wk

Poor

No

   

OM-19

62

M

I (T1, N1 M0)

+

No

70 Gy

Cis 100 Q3wk

Poor

No

   

OM-24

59

M

II (T3, N1, M0)

+

Yes Margin (+/−)

66 Gy

Cis 40 Weekly

Excellent

Yes

   

OM-28

50

M

II (T2, N2, M0)

+

No

70 Gy

Cis 100 Q3wk

Excellent

Yes

   

OM-29

73

M

I (T2, N1, M0)

+

No

70 Gy

Cis 40 Weekly

Excellent

No

   

OM-31

72

M

I (T1, N1, M0)

+

Yes

70 Gy

Cis 40 Weekly

Excellent

No

   

OM-33

63

M

I (T0, N1, M0)

+

Yes

70 Gy

Carbo/ Tax

Excellent

No

   
  1. Subjects included in the study. Cancer stage classification is according to AJCC Cancer Staging Manual28. P16 state was determined using standard immunohistochemistry for P16, a surrogate marker for oncogenic HPV infection. Surgical resection was performed when feasible and included partial glossectomy, floor of mouth resection, mandibular resection and cervical lymph nodes dissection, tonsillectomy, and selective cervical lymphadenectomy based on each tumour site of origin and extent of involvement. Radiation therapy was performed in all patients as intensity-modulated radiation therapy (IMRT). The prescribed dose was 70 Gy in 35 fractions for most cases, with lower doses (60 Gy in 30 fractions or 66 Gy in 33 fractions) applied in selected cases, based on the patient’s tolerability. Adjuvant chemotherapy was performed in all, but one patient and followed one of the following four regimens: high dose cisplatin (Cisplatin 100 mg/m2 given once every 3 weeks), low dose cisplatin (Cisplatin 40 mg/m2 once a week), Carbo/Tax regimen (weekly Carboplatin and paclitaxel (Taxol) administration) or Carbo/5Fu (Carboplatin and 5-Fluorouracil). Excellent dentition was classified as healthy appearing gums and teeth with no visible cavities of decay. Poor dentition was significant gum recession, grossly visible cavities or unrestorable decayed teeth. Additional metadata is presented in the Supplementary Tables S1, S2.